+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Engineering Microorganisms into Powerful Micromachines: Can Synthetic Biology Foster Bio-Revolution?

  • PDF Icon

    Report

  • 72 Pages
  • October 2021
  • Region: Global
  • GlobalData
  • ID: 5460108
Engineering Microorganisms into Powerful Micromachines: Can Synthetic Biology Foster Bio-Revolution?​

Summary


Achieving global goals such as mass-scale food production and sustainable low-cost manufacturing methods is the need of the hour. Synthetic Biology (SynBio) is a field of science that has grown over the last two decades to emerge as a mature area in biological engineering with its potential to reduce the costs of biological production methods and improve the global food supply. It also can be crucial to create patient-centric drugs and promote precision medicine for better health outcomes. This report highlights the importance of SynBio in the design and creation of biological entities that do not exist in nature or reengineer existing biological systems to develop products like medicines, chemicals, ingredients, and advanced materials to revolutionize the way we live and build a sustainable economy.

SynBio overview and its key applications across industries, use-cases and major stakeholders in each industry, the noise created in the media, VC investment trends, real-world innovation use cases and examples related to the implementation of SynBio, trends in patent filings and grants, and the future potential of SynBio.

Scope


  • Technology Decoding: presents the technology overview, key features, market drivers, major applications, and a market map with potential use cases and popular players (startups as well as enterprises).
  • Media Analysis: highlights the technology presentation from the media perspective - major news, and lauds from the social media promoting the technology. Also, includes mentions of the technology from company annual and other filings.
  • Investment Radar: outlines the venture capital funding trends with some of the popular deals, the most funded startups, and notable investors and accelerators pumping millions into the technology growth.
  • Innovation Explorer: introduces game-changing company innovations with a spotlight on startups. Select corporate-startup partnerships inclined at future product developments are also mentioned.
  • IP Landscaping: provides a broad-level analysis of the trends in patent filings and grants, priority countries, and key patent filers in the technology.
  • The Road Ahead: summarizes the drivers and challenges, use cases that can become successful with business leaders, potential applications in new horizons, and the outlook of the technology.

Reasons to Buy


  • this FutureTech Series Reports are aimed at capturing futuristic technologies which have the potential to disrupt tomorrow.
  • These technologies are constantly changing, adapting, and progressing to enable a paradigm shift in our daily lives.
  • The awareness, knowledge, and expertise of these topics help transform business models and strategic thinking with an in-depth understanding of mega trends that can directly influence patenting, collaboration, acquisition, and investment decisions.

Table of Contents

1. Technology Decoding: overview

2. Media Analysis: News publication trends, Thought leadership, Social media traction, Company filings

3. Investment Radar: VC investment trends, Top countries by most deals, Top funded startups, Most active investors and accelerators

4. Innovation Explorer: Key innovators: startups under spotlight and major enterprises in action

5 IP Landscaping: IP Filing trends

6 Road Ahead: Drivers and challenges, Emerging concepts, Potential use cases for business leaders, Futuristic industry applications, Outlook

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 10X Genomics
  • 23&me
  • 4DMT
  • AB InBev
  • Abbvie
  • Absci
  • ADM
  • Adrestia
  • AgBiome
  • Agilent
  • Agrigenetics
  • Agrimetis
  • Agrivida
  • Air Protein
  • Alexandria Real Estate Equity Inc
  • Allonnia
  • Amgen
  • Amunix
  • Amyris
  • Andes
  • Antheia
  • Apeel Biosciences
  • AquaBounty Technologies
  • ARCH Venture Capital
  • Arkema
  • Arsenal Bio
  • Artios
  • Artiva
  • Arzeda
  • Asimov
  • AstraZeneca
  • Atlas Venture Inc
  • Atomwise
  • AzarGen Biotechnologies
  • Azitra
  • Bactolife
  • BASF
  • BASF Venture Capital
  • Bayer
  • Beam Therapeutics
  • Beijing Biocytogen
  • Benson Hill
  • BEOnChip
  • BGI
  • Biogen
  • Biomason
  • Bio-Rad
  • Biota
  • Bolt Therapeutics
  • Bolt Threads
  • Bota Biosciences
  • BP
  • Bristol Meyers
  • Bruker
  • Calysta
  • Calyxt
  • Cargill
  • Caribou Biosciences
  • Celgene
  • Cellarity
  • Cellectis
  • CG Oncology
  • China National Chemical Corp
  • Chromatin
  • CinderBio
  • Clara Foods
  • Clariant
  • Coca Cola
  • Codexis
  • Conagen
  • Corbion
  • Corteva
  • Cysbio
  • Danaher
  • Decode Genetics
  • Dell
  • Dow
  • DSM
  • Dupont
  • Editas Medicine
  • Editas Medicine
  • eGenesis
  • eGenesis
  • Elevate Bio
  • ElevateBio
  • Eligo Bioscience
  • EnginZyme
  • Evolva Holdings
  • Evolve Biosystems
  • Evonik
  • ExxonMobil
  • Flagship Pioneering
  • Future Fields
  • Future Meat
  • GE Research
  • Genecis
  • Genedata
  • Genome Company
  • Genomic Vision
  • Genopole
  • Gent Bio
  • Gingko Bioworks
  • GlycosBio
  • Google
  • GreenLight Biosciences
  • GRO Biosciences
  • Hera BioLabs
  • Hexagon Bio
  • Hitachi
  • Hookipa Biotech
  • Hoxton Farms
  • Huawei
  • Human Genome Sciences
  • Humane Genomics
  • IBM
  • ICRISAT
  • igenebio
  • Illumina
  • Impossible Foods
  • Inari
  • Inc.
  • Industrial Microbes
  • Ineos
  • Inscripta
  • Insitro
  • GlaxoSmithKline
  • Integrated DNA Technologies
  • J&J
  • JLabs
  • Johnson & Johnson
  • Just Foods
  • Kaiima
  • Keygene
  • Kheiron
  • Khosla Ventures
  • Kinnva
  • Kite Pharma
  • Kriya Therapeutics
  • L’Oreal
  • L’oreal
  • Lab Central
  • Lanzatech
  • Leaps by Bayer
  • Light Bio
  • Lonza
  • Lululemon
  • Lux Capital
  • Lygos
  • Mammoth Biosciences
  • Manus Bio
  • Meatable
  • Merck
  • Merck
  • Michelin
  • Microsoft
  • Modern Meadow
  • Monsanto
  • Mosa Meat
  • Motif
  • Mussel Polymers
  • Nature’s Sources
  • Nebula Genomics
  • New Age Meats
  • Nike
  • Nomad Foods
  • Novartis
  • Novartis Ventures
  • Novo Nordisk Foundation
  • Novoloop
  • Novozymes
  • NRGene
  • Omega Therapeutics
  • Orbimed Ventures
  • Origin Bio
  • Outpace
  • P&G
  • Pandion Therapeutics
  • Pepsico
  • Perfect Day
  • Perkin Elmer
  • Pfizer
  • Pfizer
  • Pfizer Ventures
  • Photanol
  • Pivot Bio
  • Plant Sensory Systems
  • Polaris Private Equity
  • Poseida Therapeutics
  • Precigen
  • Precision Biosciences
  • rBio
  • Recombinetics Inc.
  • Recursion
  • Redefine Meats
  • Regeneron Pharmaceuticals
  • Reliance Industries Limited
  • Resilience
  • Roche
  • S.V Health Ventures
  • SABIC
  • Saint-Gobain
  • Samsung
  • Sanatech Seeds
  • Sangamo
  • Sankyo Co Ltd
  • Sanofi
  • Scribe Therapeutics
  • Seattle Genetics
  • Second Genome
  • SentiBio
  • Shape Therapeutics
  • Shell
  • Shenyang Tonglian
  • Sherlock Biosciences
  • Sinopec
  • Siolta Therapeutics
  • Soffinova Ventures
  • Sonoma
  • Sony
  • Spiber
  • Startup Health
  • Stratcode
  • Sumitomo
  • Syngenta
  • Synlogic
  • Synthace
  • Synthego
  • Synthekine
  • Tata Chemicals
  • Terravia
  • TeselaGen
  • Thermo Fischer
  • Thermo Fisher Scientific
  • Triton Algae Innovations
  • Twist Biosciences
  • Unilever
  • Unilever
  • Upside Foods
  • Verily
  • Verve Therapeutics
  • Viridos
  • Zymergen
  • Visolis
  • Vivet Therapeutics
  • WarpBio
  • Werewolf Therapeutics
  • Y Combinator
  • Yara
  • Zydus Cadilla
  • Zymergen
  • ZymoChem